Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
144
resultados
Última actualización
07/05/2025 [07:12:00]
Resultados 100 a 125 de 144
Resumen de: AU2023276693A1
The present disclosure relates, inter alia, to methods of treating ulcerative colitis with therapeutic intestinal alkaline phosphatases.
Resumen de: CN118995910A
The invention relates to application of Terrisporobacter spp as a marker in a product for assisting in predicting the curative effect of VDZ on ulcerative colitis, and belongs to the technical field of molecular biomedicine. The invention provides Terrisporobacter spp, and application of Terrisporobacter spp as a marker in a product for assisting in predicting the curative effect of VDZ on ulcerative colitis. According to the application, Terrisporobacter spp is selected as the marker for predicting the curative effect of treating UC by VDZ, UC patients can be distinguished to be sensitive to VDZ and not sensitive to VDZ, early diagnosis is conducted on VDZ sensitive patients, and the application has the advantages of being high in accuracy and sensitivity.
Resumen de: ES2988838A1
Method to predict the response of Crohn's disease patients to anti-TNF-α therapy based on plasma levels of vinculin together with the Crohn's disease activity index (CDAI), corticosteroid induction and bowel resection. (Machine-translation by Google Translate, not legally binding)
Resumen de: WO2024236584A1
Methods of diagnosing inflammatory bowel disease (IBD), ulcerative colitis (UC) or Crohn's disease (CD) in a subject in need thereof, comprising receiving a stool sample from the subject and measuring DNA levels in the stool sample are provided. Kits comprising at least one reagent that detects mammalian DNA and not bacterial DNA and at least one reagent that detects cell type-specific DNA methylation are also provided.
Resumen de: WO2024239006A1
The present disclosure provides methods and compositions for determining the risk of a patient being non-responsive to a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody and methods and compositions for treating inflammatory bowel disease (IBD) with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.
Resumen de: US2024383882A1
The present invention discloses a number of polycyclic amines that are useful as opioid receptor modulators. The compounds of the invention are useful in both therapeutic and diagnostic methods, including for treating pain, neurological disorders, cardiac disorders, bowel disorders, drug and alcohol addiction, drug overdose, urinary disorders, respiratory disorders, sexual dysfunction, psoriasis, graft rejection or cancer.
Resumen de: US2024384349A1
The invention relates to the identification of biomarkers of the response status of a patient for a treatment with anti-TNFalpha agents, for treatment with anti-α4β7 agents or with both anti-TNFalpha agent and anti-α4β7 agents and to their use in assessing such status, in particular for assessing nonresponsive status for a treatment with anti-TNFalpha agents or respectively with anti-α4β7 agent in human patients suffering from inflammatory condition or disease, in particular Inflammatory Bowel Disease (IBD), in particular Ulcerative Colitis or Crohn's disease. The invention describes a method of in vitro assessing whether a treatment with anti-TNFalpha agent or with with anti-α4β7 agent may be useful in a human suffering from inflammatory condition or disease, in particular when said condition or disease is a chronic and/or relapsing one, particularly a gastrointestinal, more particularly intestinal, inflammatory condition or disease which is eligible for treatment with anti-TNFalpha agent or respectively with anti-α4β7 agent.
Resumen de: CN118979093A
The invention relates to the technical field of poultry pathogenic bacterium detection, in particular to a detection culture medium, a preparation method of the detection culture medium, a kit and a method for detecting chicken necrotic enteritis by applying the detection culture medium. The invention discloses a detection culture medium, a preparation method of the detection culture medium, a kit and a method for detecting chicken necrotic enteritis by using the detection culture medium. The content of clostridium perfringens in the excrement sample is judged according to the color change degree and the color change time, and then the infection degree of the chicken necrotic enteritis is obtained. Therefore, the method can be used for rapid detection on a breeding site, and has a wide application prospect.
Resumen de: US2024376210A1
A method for treating a human patient suffering from fistulizing Crohn's disease, comprising administering to a patient suffering from fistulizing Crohn's disease, a humanized antibody having binding specificity for human α4β7 integrin, wherein the human patient has a seton that was surgically placed prior to administration of the antibody, and wherein the dosing regimen induces fistula (e) healing.
Resumen de: MX2020013157A
Provided are methods of treatment of a sphingosine 1-phosphate subtype 1 (S1P<sub>1</sub>) receptor-associated disorder comprising prescribing and/or administering to an individual in need thereof a standard dose of (<i>R</i>)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1, 2,3,4-tetrahydrocyclopenta<i>b</i>indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
Resumen de: CN118957046A
The invention belongs to the technical field of medicine preparation, and particularly relates to an intestinal injury and intestinal flora protection method which comprises the following specific operation steps: S1, experimental sample selection and grouping: selecting 360 1-day-old specific pathogen-free SPF white leghorns for an experiment, randomly dividing the white leghorns into 6 groups, repeating 6 in each group, and selecting a sample; according to the application, a chicken in-vivo salmonella infection model is constructed, various data indexes are integrated, the effect is optimal when the puerarin dosage is 100mg/kg, the puerarin has a protection effect on salmonella challenge, the growth performance of chickens can be improved, the damage of intestinal epithelial villus is improved, the anti-inflammatory effect is exerted, and the immune system of the body is protected. In addition, microbe 16S rRNA analysis finds that puerarin can resist inflammation and damage induced by salmonella by adjusting intestinal flora. Research results of the application show that puerarin has potential in the aspects of replacing antibiotics to control salmonella infection in poultry production and improving food safety.
Resumen de: WO2024233362A1
Provided herein are methods of treating an inflammatory bowel disease (IBD) in a subject by administering to the subject a thiopurine drug for the treatment of IBD, the subject not comprising an at risk genetic variant or serological marker. Also provided herein are related compositions, uses, system, and kits.
Resumen de: US2024376210A1
A method for treating a human patient suffering from fistulizing Crohn's disease, comprising administering to a patient suffering from fistulizing Crohn's disease, a humanized antibody having binding specificity for human α4β7 integrin, wherein the human patient has a seton that was surgically placed prior to administration of the antibody, and wherein the dosing regimen induces fistula (e) healing.
Resumen de: WO2024228570A1
The present invention relates to discovery of a target for inhibiting fibrosis in inflammatory bowel disease, and prediction of the progression of fibrosis in inflammatory bowel disease by using same. The present inventors, who are researchers, have found that NOX4 transcripts are detected at low levels in a normal colon, but NOX4 expression is up-regulated in drug-resistant fibrostenosis patients with UC or Crohn's disease (CD) and in a dextran sulfate sodium (DSS)-induced mouse colitis model, and thus it is hypothesized that NOX4 contributes to intestinal fibrosis damage of ulcerative colitis and TGF-β signaling is required to induce fibrosis development. In order to test this hypothesis, the present inventors established Nox4 deficient mice (Nox4-/-) with DSS-induced colitis, and investigated the effect of Nox4 on the response to intestinal injury. This study is expected to be widely used to predict whether fibrosis proceeds in inflammatory bowel diseases and inhibit same.
Resumen de: EP4417707A2
This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.
Resumen de: CN118924920A
The invention discloses a neutrophil elastase activated near-infrared two-region fluorescent carbon dot and application thereof in diagnosis of inflammatory bowel diseases. The neutrophil elastase activated near-infrared two-region fluorescent carbon dot is obtained by combining a carbon dot synthesized by a solvothermal method with pentafluoropropionic anhydride through a covalent bond. The carbon dot disclosed by the invention can perform specific and sensitive response on neutrophil elastase with high biocompatibility in cells and in vivo, shows a strong NIR-II fluorescence signal, and can be used for real-time imaging of noninvasive diagnosis evaluation of early inflammatory bowel diseases; and a potential method is provided for developing a clinical non-invasive early inflammatory bowel disease diagnosis technology.
Resumen de: US2023203591A1
Provided herein are materials and methods for isolation of eukaryotic nucleic acid from a human or non-human animal stool sample. Also provided are methods of analysis of eukaryotic biomarkers present in a human or non-human animal stool sample.
Resumen de: CN118903262A
The invention provides radix paeoniae alba and semen raphani bowel-relaxing granules as well as a preparation method and a quality detection method thereof. The radix paeoniae alba and semen raphani bowel-relaxing granules are prepared from the following raw material medicines in parts by weight: 800 to 1200 parts of fried radix paeoniae alba, 800 to 1200 parts of fried semen raphani and 200 to 350 parts of fructus cannabis. Weighing parched white peony roots, parched radish seeds and fructus cannabis, adding water to decoct, filtering, combining filtrate obtained by filtering each time, and concentrating under reduced pressure; weighing dextrin, putting the dextrin into a fluidized bed, setting the air inlet amount and the air inlet temperature, and atomizing and drying the concentrated solution to obtain the paeonia lactiflora laxative granules. The quality detection method consists of identification and content determination, the identification is to identify parched white peony root and parched radish seed by utilizing a thin layer chromatography, and the content determination is to determine the content of parched white peony root in the paeonia lactiflora laxative granules by utilizing a high performance liquid chromatography. The paeonia lactiflora laxative granules prepared by the invention are mild in drug property, do not contain anthraquinone components, and dredge the body without hurting healthy qi. The quality detection method is high in accuracy, and the medici
Resumen de: JP2024159821A
To provide methods and treatment involving excess free LIGHT.SOLUTION: The present disclosure relates to methods of detecting free (active) LIGHT in biological samples to diagnose conditions associated with elevated free LIGHT and to predict the effectiveness of anti-LIGHT therapies. The disclosure also relates to treating such conditions with anti-LIGHT antibodies. The conditions include acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), where the ALI and ARDS are optionally associated with viral infection, including coronavirus infection. The conditions also include Crohn's disease or an inflammatory condition associated with Crohn's disease.SELECTED DRAWING: Figure 10
Resumen de: CN118910056A
The invention belongs to the technical field of animal genetic engineering, and particularly relates to a small interfering RNA for regulating and controlling the barrier function of cell intestinal epithelial cells, an overexpression vector and application of the overexpression vector. The small interfering RNA provided by the invention is named si-SLC26A3-1, and after a solute-related vector 26A3 gene SLC26A3 is interfered by using the small interfering RNA, mucoprotein, tight junction protein and the like secreted by intestinal epithelial cells are remarkably reduced, which indicates that the barrier function of the intestinal epithelial cells is damaged. After cells are transfected by using the overexpression vector, mucoprotein, tight junction protein and the like secreted by intestinal epithelial cells are remarkably up-regulated, which indicates that the barrier function of the intestinal epithelial cells is enhanced. The small interfering RNA and the overexpression vector provided by the invention can regulate and control the barrier function of the epithelial cells of the pig intestines, and a feasible method is provided for construction and targeted therapy of IBD models of pigs and people based on the similarity of the pigs and the people in the aspects of anatomy, physiology, heredity and the like.
Resumen de: MX2024011979A
The disclosure provides pharmaceutical compositions comprising a therapeutically effective amount of compound (A), compound (B), compound (C), compound (D), compound (E), compound (F), compound (G), compound (H), compound (J), compound (K), compound (L), compound (M), compound (N), compound (O), compound (P), or compound (Q)or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient: Also provided are dosage units comprising one or more of compound (A), compound (B), compound (C), compound (D), compound (E), compound (F), compound (G), compound (H), compound (J), compound (K), compound (L), compound (M), compound (N), compound (O), compound (P), or compound (Q) or the pharmaceutical compositions described herein, methods of treating an inflammatory bowel disease in a subject in need thereof, or methods of modulating an inflammatory bowel disease marker in a subject in need thereof.
Resumen de: CN118909916A
Disclosed herein are methods for the in vitro differentiation of precursor cells into definitive endoderm by modulating the signaling pathway, which definitive endoderm can be further differentiated into human colon organoids (HCOs). Further disclosed are HCOs and methods of using HCOs, which may be used, for example, for HCOs to determine the efficacy and/or toxicity of potential therapeutic agents against a disease selected from the group consisting of colitis, colon cancer, polyp syndrome and/or irritable bowel syndrome.
Resumen de: CN118910292A
The invention relates to a biomarker for diagnosis of VEO-IBD and IL10RA mutation enteritis. The defects that in the prior art, existing IBD diagnosis mostly depends on blood detection, endoscope and other invasive and invasive examinations, the screening detection threshold is high, certain risks exist, the medical compliance is poor, and misdiagnosis and missed diagnosis are likely to happen are overcome.
Resumen de: CN118910203A
The invention discloses application of a serum marker in preparation of a kit for evaluating the curative effect of mesenchymal stem cells on Crohn's disease, and relates to the technical field of medical treatment, and the serum marker is a composition at least composed of 4-guanidine butyraldehyde, beta-D-glucopyranosyl gluconic acid and a prolyl arginine isomer 1. Based on an isotope labeled liquid chromatography-mass spectrometry technology, the treatment effectiveness biomarker is screened by detecting the change of serum metabolites before and after the placenta-derived mesenchymal stem cells are used for treating a mouse suffering from the Crohn disease, the diagnosis efficiency of the biomarker is evaluated, and data support is provided for clinical transformation of the mesenchymal stem cells for treating the Crohn disease.
Nº publicación: US2024371490A1 07/11/2024
Solicitante:
CHILDRENS HOSPITAL MED CT [US]
Children's Hospital Medical Center
Resumen de: US2024371490A1
Disclosed are methods for determining an initial or subsequent dose of an anti-tumor necrosis factor α (anti-TNFα) biologic for administering to an individual having an inflammatory condition, based on, in part, determining in the individual a level of one or more time-varying covariates selected from weight, albumin, erythrocyte sedimentation rate (ESR), neutrophil CD64 (nCD64) expression, and combinations thereof, and applying a correction factor to account for the changes in covariates over time. The inflammatory condition may be one selected from an IBD, such as Crohn's Disease (CD) or Ulcerative Colitis (UC), or inflammatory conditions such as uveitis or rheumatoid arthritis.
BOPI
Sede Electrónica
